Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Samia Mora, M.D.

Co-Author

This page shows the publications co-authored by Samia Mora and Paul Ridker.
Connection Strength

11.897
  1. Response to letter regarding article, "High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy". Circulation. 2014 Apr 29; 129(17):e481.
    View in: PubMed
    Score: 0.575
  2. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014 Feb 04; 129(5):553-61.
    View in: PubMed
    Score: 0.560
  3. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013 Sep 10; 128(11):1189-97.
    View in: PubMed
    Score: 0.549
  4. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol. 2012 Apr 24; 59(17):1521-8.
    View in: PubMed
    Score: 0.500
  5. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010 Aug; 56(8):1252-60.
    View in: PubMed
    Score: 0.438
  6. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 May; 59(5):1153-60.
    View in: PubMed
    Score: 0.430
  7. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010 Mar 09; 121(9):1069-77.
    View in: PubMed
    Score: 0.430
  8. Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27,331 women. Clin Chem. 2009 May; 55(5):888-94.
    View in: PubMed
    Score: 0.407
  9. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 Feb 24; 119(7):931-9.
    View in: PubMed
    Score: 0.400
  10. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation. 2008 Sep 02; 118(10):993-1001.
    View in: PubMed
    Score: 0.387
  11. Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events. Circulation. 2006 Aug 01; 114(5):381-7.
    View in: PubMed
    Score: 0.336
  12. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006 Mar 22; 295(12):1412-9.
    View in: PubMed
    Score: 0.328
  13. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol. 2006 Jan 16; 97(2A):33A-41A.
    View in: PubMed
    Score: 0.321
  14. Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiol. 2021 04 01; 6(4):437-447.
    View in: PubMed
    Score: 0.232
  15. Association of the Mediterranean Diet With Onset of Diabetes in the Women's Health Study. JAMA Netw Open. 2020 11 02; 3(11):e2025466.
    View in: PubMed
    Score: 0.226
  16. Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial. J Am Heart Assoc. 2020 09; 9(17):e016507.
    View in: PubMed
    Score: 0.222
  17. Group IIA Secretory Phospholipase A2, Vascular Inflammation, and Incident Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019 06; 39(6):1182-1190.
    View in: PubMed
    Score: 0.204
  18. Assessment of Risk Factors and Biomarkers Associated With Risk of Cardiovascular Disease Among Women Consuming a Mediterranean Diet. JAMA Netw Open. 2018 12 07; 1(8):e185708.
    View in: PubMed
    Score: 0.198
  19. Evaluation of the Pooled Cohort Risk Equations for Cardiovascular Risk Prediction in a Multiethnic Cohort From the Women's Health Initiative. JAMA Intern Med. 2018 09 01; 178(9):1231-1240.
    View in: PubMed
    Score: 0.194
  20. Lipoprotein(a) and Cardiovascular Risk Prediction Among Women. J Am Coll Cardiol. 2018 07 17; 72(3):287-296.
    View in: PubMed
    Score: 0.192
  21. Circulating Branched-Chain Amino Acids and Incident Cardiovascular Disease in a Prospective Cohort of US Women. Circ Genom Precis Med. 2018 04; 11(4):e002157.
    View in: PubMed
    Score: 0.189
  22. Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study. Am J Epidemiol. 2018 04 01; 187(4):705-716.
    View in: PubMed
    Score: 0.189
  23. Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very-Low-Density Lipoproteins. J Am Heart Assoc. 2017 Dec 09; 6(12).
    View in: PubMed
    Score: 0.185
  24. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2017 Jul 21; 6(7).
    View in: PubMed
    Score: 0.180
  25. Lipoprotein insulin resistance score and risk of incident diabetes during extended follow-up of 20 years: The Women's Health Study. J Clin Lipidol. 2017 Sep - Oct; 11(5):1257-1267.e2.
    View in: PubMed
    Score: 0.179
  26. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017 Jun 20; 135(25):2494-2504.
    View in: PubMed
    Score: 0.177
  27. Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clin Chem. 2017 04; 63(4):870-879.
    View in: PubMed
    Score: 0.174
  28. Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS One. 2016; 11(11):e0165615.
    View in: PubMed
    Score: 0.172
  29. Circulating N-Linked Glycoprotein Side-Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. J Am Heart Assoc. 2016 07 13; 5(7).
    View in: PubMed
    Score: 0.167
  30. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 05 01; 1(2):136-45.
    View in: PubMed
    Score: 0.165
  31. Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circ Res. 2016 Apr 01; 118(7):1106-15.
    View in: PubMed
    Score: 0.163
  32. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016 May 01; 37(17):1373-9.
    View in: PubMed
    Score: 0.163
  33. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial. Circulation. 2015 Dec 08; 132(23):2220-9.
    View in: PubMed
    Score: 0.158
  34. Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. Clin Chem. 2015 Sep; 61(9):1156-63.
    View in: PubMed
    Score: 0.155
  35. Novel protein glycan side-chain biomarker and risk of incident type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2015 Jun; 35(6):1544-50.
    View in: PubMed
    Score: 0.154
  36. Response to letter regarding article, "lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)". Circulation. 2014 Oct 21; 130(17):e152.
    View in: PubMed
    Score: 0.149
  37. A novel protein glycan biomarker and future cardiovascular disease events. J Am Heart Assoc. 2014 Sep 23; 3(5):e001221.
    View in: PubMed
    Score: 0.148
  38. Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (<30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER). Am J Cardiol. 2014 Dec 01; 114(11):1682-9.
    View in: PubMed
    Score: 0.148
  39. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014 Feb 11; 129(6):635-42.
    View in: PubMed
    Score: 0.139
  40. Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med. 2011 Dec 06; 155(11):742-50.
    View in: PubMed
    Score: 0.122
  41. Lifestyle interaction with fat mass and obesity-associated (FTO) genotype and risk of obesity in apparently healthy U.S. women. Diabetes Care. 2011 Mar; 34(3):675-80.
    View in: PubMed
    Score: 0.115
  42. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet. 2010 Jul 31; 376(9738):333-9.
    View in: PubMed
    Score: 0.111
  43. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 2009 Nov; 5(11):e1000730.
    View in: PubMed
    Score: 0.106
  44. Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007 Nov 06; 116(19):2110-8.
    View in: PubMed
    Score: 0.091
  45. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18; 298(3):309-16.
    View in: PubMed
    Score: 0.090
  46. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. Clin Chem. 2007 May; 53(5):845-51.
    View in: PubMed
    Score: 0.087
  47. Phenotypic and Genotypic Associations Between Migraine and Lipoprotein Subfractions. Neurology. 2021 11 30; 97(22):e2223-e2235.
    View in: PubMed
    Score: 0.060
  48. Sugar-Sweetened Beverage Consumption May Modify Associations Between Genetic Variants in the CHREBP (Carbohydrate Responsive Element Binding Protein) Locus and HDL-C (High-Density Lipoprotein Cholesterol) and Triglyceride Concentrations. Circ Genom Precis Med. 2021 08; 14(4):e003288.
    View in: PubMed
    Score: 0.059
  49. Association of Plasma Branched-Chain Amino Acid With Biomarkers of Inflammation and Lipid Metabolism in Women. Circ Genom Precis Med. 2021 08; 14(4):e003330.
    View in: PubMed
    Score: 0.059
  50. Hypothyroidism and Kidney Function: A Mendelian Randomization Study. Thyroid. 2020 03; 30(3):365-379.
    View in: PubMed
    Score: 0.054
  51. Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study. JAMA Cardiol. 2019 02 01; 4(2):144-152.
    View in: PubMed
    Score: 0.050
  52. Gene-Based Elevated Triglycerides and Type 2 Diabetes Mellitus Risk in the Women's Genome Health Study. Arterioscler Thromb Vasc Biol. 2019 01; 39(1):97-106.
    View in: PubMed
    Score: 0.050
  53. Lipoprotein Particle Profiles, Standard Lipids, and Peripheral Artery Disease Incidence. Circulation. 2018 11 20; 138(21):2330-2341.
    View in: PubMed
    Score: 0.049
  54. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 2018 10 13; 392(10155):1311-1320.
    View in: PubMed
    Score: 0.049
  55. Adiposity and Genetic Factors in Relation to Triglycerides and Triglyceride-Rich Lipoproteins in the Women's Genome Health Study. Clin Chem. 2018 01; 64(1):231-241.
    View in: PubMed
    Score: 0.046
  56. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. J Am Heart Assoc. 2017 Aug 03; 6(8).
    View in: PubMed
    Score: 0.045
  57. Lipid biomarkers and long-term risk of cancer in the Women's Health Study. Am J Clin Nutr. 2016 06; 103(6):1397-407.
    View in: PubMed
    Score: 0.041
  58. Differential Genetic Effects on Statin-Induced Changes Across Low-Density Lipoprotein-Related Measures. Circ Cardiovasc Genet. 2015 Oct; 8(5):688-95.
    View in: PubMed
    Score: 0.039
  59. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 Caucasians. PLoS One. 2015; 10(4):e0120758.
    View in: PubMed
    Score: 0.038
  60. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014 Aug 05; 64(5):485-94.
    View in: PubMed
    Score: 0.037
  61. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013 Nov; 45(11):1345-52.
    View in: PubMed
    Score: 0.035
  62. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013 Nov; 45(11):1274-1283.
    View in: PubMed
    Score: 0.035
  63. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013 Oct 01; 128(14):1504-12.
    View in: PubMed
    Score: 0.034
  64. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012 Mar 28; 307(12):1302-9.
    View in: PubMed
    Score: 0.031
  65. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov; 8(11):e1001116.
    View in: PubMed
    Score: 0.030
  66. The fat-mass and obesity-associated (FTO) gene, physical activity, and risk of incident cardiovascular events in white women. Am Heart J. 2010 Dec; 160(6):1163-9.
    View in: PubMed
    Score: 0.028
  67. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J. 2007 Dec; 28(23):2937-43.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.